IDgenetix® Test Report Features

IDgenetix

Laboratory Test Report

Patient Name:	Patient ID:	Age:	Gender:	DOB:
Doe, Jane	AC900-B	70	Female	10/14/1950

Sample Type:	Date Collected:	Date Received:	Ordering Physician:	Client/Account #:
Buccal Swab	11/09/2020	11/09/2020	Cullors Ali	CAli910

Test Ordered:	Indication:	Report Date:	Report Status:
NeuroIDgenetix 902	NeuroIDgenetix	06/25/2021	Draft

PHARMACOGENETIC TESTING BASED TREATMENT GUIDANCE

Depression Drug Therapy Selection & Dosing Guidance

1 Use as Directed

Drug
paroxetine (SSRI) [1]
desvenlafaxine (SNRI)
duloxetine (SNRI)
levomilnacipran (SNRI)
venlafaxine (SNRI)
bupropion (NDRI) [1]
mirtazapine (NaSSA) [1]
trazodone (SARI)
vilazodone (SRI)
vortioxetine (Serotonin Modulator and Stimulator)
desipramine (TCA) [1]
nortriptyline (TCA) [1]
aripiprazole (SGA) [1]
brexpiprazole (SGA)
quetiapine (SGA) [1]

2 Use With Caution and/or Increased Monitoring — **3**

Drug	Dosing
▸▸ citalopram	Consider dose adjustment or alternate drug. A 50% starting dose reduction is recommended by CPIC with titration to response (CYP2C19 PM), which may be delayed due to COMT variant. Note: drug label advises 20mg/day maximum for PMs given increased QT prolongation risk. PubMedID: 25974703
escitalopram	Consider dose adjustment or alternate drug. Per CPIC guideline, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19 (CYP2C19 PM). Greatly reduced metabolism, higher plasma concentrations may increase the probability of side effects. PubMedID: 25974703
sertraline	Consider dose adjustment or alternate drug. Per CPIC guideline, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19. Greatly reduced metabolism, higher plasma concentrations may increase the probability of side effects (CYP2C19 PM). PubMedID: 25974703
amitriptyline [1]	Consider dose adjustment or alternate drug. Consider 50% reduction of recommended starting dose (CYP2C19 PM). Utilize therapeutic drug monitoring to guide dose adjustments. CPIC Guideline PubMedID: 23486447
doxepin [1]	Consider dose adjustment or alternate drug. Consider 50% reduction of recommended starting dose (CYP2C19 PM). Utilize therapeutic drug monitoring to guide dose adjustments. CPIC Guideline PubMedID: 23486447
imipramine [1]	Consider dose adjustment or alternate drug. Consider 50% reduction of recommended starting dose (CYP2C19 PM). Utilize therapeutic drug monitoring to guide dose adjustments. CPIC Guideline PubMedID: 23486447
fluoxetine *	Risk of metabolic interaction with citalopram
fluvoxamine *	Risk of metabolic interaction with citalopram

4

LABORATORY RESULTS AND PHARMACOGENETIC TEST ANALYSIS

5 Gene	Star Allele Genotype/Diplotype	6 Metabolizer Phenotype PM/IM/EM/UM	7 Clinically Significant
ABCB1 [NM_000927.4:c.3435C>T]	T/T	N/A	No
ADRA2A -1291C>G [NM_000681.3:c.-1252G>C]	C/G	N/A	No
COMT [NM_000754.3:c.472G>A]	A/A	N/A	Yes
CYP1A2	*1/*1	EM	No
CYP2C19	*2/*2	PM	Yes
CYP2C9	*1/*1	EM	No
CYP2D6	*1/*1	EM	No
CYP3A4	*1/*1	EM	No
CYP3A5	*1/*1	EM	No
HTR2A [NM_000621.4:c.-998G>A]	A/G	N/A	No
HTR2A [NM_000621.4:c.614-2211T>C]	C/T	N/A	No
HTR2C [NM_000868.2:c.-697G>C]	C/G	N/A	No
HTR2C [NM_000868.2:c.-759C>T]	C/T	N/A	No
HTR2C [NM_000868.2:c.68G>C]	G/G	N/A	No
MTHFR A1298C [NM_005957.3:c.1286A>C]	A/C	N/A	No
MTHFR C677T [NM_005957.3:c.665C>T]	C/T	N/A	No
NAT2	*4/*4	RA	No
OPRM1 [NM_000914.3:c.118A>G]	A/A	N/A	No
SLC6A4 5-HTTLPR	Long/Long	N/A	No
SLC6A4 [NM_001045.4:c.-1760C>T]	C/C	N/A	No

1 **"Use as Directed" Medications:** Among the genes analyzed, no genetic variants or metabolic interactions were identified that would suggest a need for increased caution or dose adjustments.

2 **"Use with Caution and/or Increased Monitoring" Medications:** One or more genetic variants or metabolic interactions have been identified that would indicate a need for increased caution, dose adjustment or selection of alternate medication.

3 **Medications** the patient is **currently taking** are highlighted.

4 **The list of patient medications provided** at the time of testing is used to display potential metabolic interactions with medications evaluated in the test panel.

5 **Genes, Genotype/Diplotype:** Genes and genetic variants analyzed and the patient's genetic variant result.

6 **Predicted drug metabolism phenotype.** *See back of test for definition of different metabolizer phenotypes.

7 **Clinically significant:** "Yes" indicates genetic variant impacts one or more messages in Use with Caution.